Graft Polymer (UK) Plc
Deal Alert: PKF supports secondary placing in connection with prospectus
Read time: 1 min
We are delighted to have supported Graft Polymer (UK) Plc in connection with the publication of a prospectus to conditionally raise £1.8m through a placing of new ordinary shares (“the Placing”). The company intends to use the net proceeds of the Placing for paying general and administrative expenses; working capital purposes; undertaking research and development; and marketing expenditure.
The company has conditionally raised £1.8 million through the Placing of 1,800,000,000 new Ordinary Shares at an issue price of 0.1 pence per new Ordinary Share.
Graft Polymer (UK) Plc is an innovative developer of biopolymer drug delivery systems aimed at enhancing the effectiveness of therapeutics for biopharmaceutical companies.
“I was thoroughly pleased with the PKF Littlejohn team for their role as the reporting accountant on the prospectus of Graft Polymer Plc. PKF provided exceptional guidance and advice, responding quickly to questions and offering timely solutions. I look forward to collaborating with their team as we continue our journey.”
Yifat Steuer, CFO
Graft Polymer (UK) Plc
PKF acted as reporting accountant on the transaction and the Transaction Services team included Adam Humphreys and Sam Bradshaw.
Find out more about how our Transaction Services team can support you and your business here.